INmune Bio, Inc. (INMB) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INMB Hot Sheet
Join SI Premium – FREE
INmune Bio, Inc. (NASDAQ: INMB) reported Q3 EPS of ($0.48), $0.08 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $43 thousand versus the consensus estimate of $46 thousand.
For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
- Host Hotels & Resorts (HST) Tops Q3 EPS by 1c; offers guidance
- Miller Industries (MLR) Misses Q3 EPS by 11c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
